Lactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked-Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studies

dc.contributor.authorBayrak, Songul
dc.contributor.authorGerni, Serpil
dc.contributor.authorOzturk, Cansu
dc.contributor.authorAlmaz, Zueleyha
dc.contributor.authorBayrak, Cetin
dc.contributor.authorKilinc, Namik
dc.contributor.authorOzdemir, Hasan
dc.date.accessioned2024-12-14T22:07:14Z
dc.date.available2024-12-14T22:07:14Z
dc.date.issued2024
dc.departmentMuş Alparslan Üniversitesien_US
dc.description.abstractCelecoxib derivatives that contain the pyrazole-linked sulfonamide moiety were synthesized, and the in vitro inhibitory impacts of the aforesaid compounds against the lactoperoxidase (LPO) enzyme were researched. To this end, LPO was purified using the affinity chromatography technique with a yield of 12.63% (319.23-fold). The results showed that the aromatic pyrazole compound (compound 1) containing 2,3-dimethoxyphenyl functional groups was the most effective LPO inhibitor with a Ki value of 3.2 +/- 0.7 nM and noncompetitive inhibition type. The second section of the study tested the previously synthesized compounds to reveal their antioxidant and antimicrobial properties. The above-mentioned compound also displayed high activity levels compared to standard antibiotics and antifungals, while all other compounds also showed antibacterial activity. In the three antioxidant methods we used, the compound with 2,5-dimethoxy phenyl groups obtained from the reaction of the aromatic pyrazole compound with propionic anhydride in the presence of NEt3 displayed the highest activity. Furthermore, molecular docking and molecular mechanics studies were conducted to complement and validate the experimental findings. The results obtained from these computational analyses are highly consistent with the experimental data.en_US
dc.identifier.doi10.1002/jbt.70055
dc.identifier.issn1095-6670
dc.identifier.issn1099-0461
dc.identifier.issue11en_US
dc.identifier.orcid0000-0001-5169-7352
dc.identifier.orcidgerni, serpil
dc.identifier.orcid0000-0001-7699-1697
dc.identifier.pmid39527602
dc.identifier.scopus2-s2.0-85208810488
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1002/jbt.70055
dc.identifier.urihttps://hdl.handle.net/20.500.12639/6460
dc.identifier.volume38en_US
dc.identifier.wosWOS:001368758800001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherWileyen_US
dc.relation.ispartofJournal of Biochemical and Molecular Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKA_20241214
dc.subjectantimicrobial and antioxidant activityen_US
dc.subjectenzyme purification and inhibitionen_US
dc.subjectlactoperoxidase (LPO)en_US
dc.subjectmolecular dockingen_US
dc.subjectpyrazole sulfonamideen_US
dc.titleLactoperoxidase Inhibition of Celecoxib Derivatives Containing the Pyrazole Linked-Sulfonamide Moiety: Antioxidant Capacity, Antimicrobial Activity, and Molecular Docking Studiesen_US
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
6460.pdf
Boyut:
1.04 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text